ライフサイエンスコーパス: relaxin

1 ion and reduced contractility in response to relaxin.

2 distal actions of low circulating levels of relaxin.

3 pression of LGR7, the cognate receptor of H2 relaxin.

4 at perfectly matches the binding cassette of relaxin.

5 nancy and its use in defining the actions of relaxin.

6 GPCR135 and GPCR142 by its high affinity for relaxin.

7 ndent activation of PPARgamma in response to relaxin.

8 d diffusive transport induced by the hormone relaxin.

9 NA diminished the regulation of PPARgamma by relaxin.

10 glucose production are corrected by chronic relaxin.

11 ion of ML290 increased p-ERK1/2 responses to relaxin.

12 bit collagen deposition similar to native H2 relaxin.

13 Relaxin-1 and its major receptor, Lgr7, mRNA are express

14 Small renal arteries isolated from relaxin-1 gene-deficient mice demonstrate enhanced myoge

15 chimeric peptides indicates the A-chain from relaxin-1, relaxin-2, insulin-like peptide (INSL)3, and

16 -h intravenous infusion of placebo (n=62) or relaxin 10 microg/kg (n=40), 30 microg/kg (n=43), 100 mi

17 ere assessed in the placebo group, 40 in the relaxin 10 microg/kg per day group, 42 in the relaxin 30

18 (dcSSc) were administered recombinant human relaxin (10 microg/kg/day or 25 microg/kg/day) or placeb

19 elaxin 30 microg/kg per day group, 37 in the relaxin 100 microg/kg per day group, and 49 in the relax

20 ive rats (SHRs), and SHRs treated with human relaxin 2 for 14 d (4 mug/h; n=8/group) and studied usin

21 or renal failure at day 60 was reduced with relaxin (2.6% [95% CI 0.4-16.8] vs 17.2% [9.6-29.6]; p=0

22 The peptide hormone human relaxin-2 (H2-RLX) has emerged as a potential therapy fo

23 Recombinant human relaxin-2 (rhRLX) stimulated PI3K/Akt B-dependent NO pro

24 er, been hampered by cross-activation of the relaxin-2 receptor, RXFP1, in the brain.

25 Serelaxin (recombinant human relaxin-2) is a peptide molecule with anti-fibrotic and

26 ptides indicates the A-chain from relaxin-1, relaxin-2, insulin-like peptide (INSL)3, and INSL6 does

27 m of the naturally occurring peptide hormone relaxin-2, is a pleiotropic vasodilating hormone that ha

28 Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many bio

29 dy, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days

30 cy of serelaxin, a recombinant form of human relaxin-2.

31 n 100 microg/kg per day group, and 49 in the relaxin 250 microg/kg per day group.

32 Human relaxin 3 (H3 relaxin) was recently discovered as a nove

33 recently identified the insulin-like peptide relaxin-3 (aka INSL7) as the endogenous ligand for an or

34 s a product of the recently identified gene, relaxin-3 (aka insulin-7 or INSL7).

35 tudy undertook to develop analogues of human relaxin-3 (H3 relaxin) that can selectively bind and act

36 one (GnRH), a G-protein-coupled receptor for relaxin-3 (RXFP3) and a functional cyclic nucleotide-gat

37 In contrast, substitution of the relaxin-3 A-chain with the A-chain from INSL5 results in

38 Because relaxin-3 also activates the relaxin receptor (LGR7), wh

39 the study of the physiological functions of relaxin-3 and GPCR135 in vivo.

40 Both relaxin-3 and its receptor (GPCR135) are expressed predo

41 The identification of relaxin-3 as the ligand for GPCR135 provides the framewo

42 gonist, R3(BDelta23-27)R/I5, consists of the relaxin-3 B-chain with a replacement of Gly23 to Arg, a

43 INSL5 inhibits (125)I-relaxin-3 binding to GPCR135 with a low potency (K(i) =

44 125I-Relaxin-3 binds GPCR135 at high affinity with a Kd value

45 was activated by nanomolar concentrations of relaxin-3 but was completely unresponsive to all other k

46 Relaxin-3 colocalized with synaptophysin in nerve termin

47 Dense relaxin-3 fiber plexuses were observed in regions of med

48 Relaxin-3 fibers were also observed in the septofimbrial

49 In lateral septum (LS), relaxin-3 fibers were concentrated in the ventrolateral

50 s, we have characterized the distribution of relaxin-3 fibers/terminals in relation to different sept

51 Relaxin-3 has previously been shown to bind and activate

52 eptides that consist of the B-chain of human relaxin-3 in combination with various A-chains from othe

53 Relaxin-3 is a neuropeptide that is implicated in the re

54 Recent studies have shown that relaxin-3 is involved in the regulation of stress and fe

55 Relaxin-3 is the only member of the insulin/relaxin supe

56 In situ hybridization showed that relaxin-3 mRNA is predominantly expressed in the dorsome

57 tested whether GPCR142 could also respond to relaxin-3 or related insulin-like molecules.

58 Recombinant human relaxin-3 potently stimulates GTPgammaS binding and inhi

59 relaxin-3, and pharmacological modulation of relaxin-3 receptors in medial septum alters hippocampal

60 not change the pharmacological properties of relaxin-3 significantly.

61 ojected to hippocampus, and contacts between relaxin-3 terminals and calbindin- and calretinin-positi

62 Human INSL5 displaces the binding of (125)I-relaxin-3 to GPCR142 with a high affinity (K(i) = 1.5 nM

63 f a very hydrophobic peptide (the A-chain of relaxin-3) with a very hydrophilic peptide (the A-chain

64 neurons express the relaxin-family peptide, relaxin-3, and pharmacological modulation of relaxin-3 r

65 euroanatomical colocalization of GPCR135 and relaxin-3, coupled with a clear high affinity interactio

66 eptor for the highly conserved neuropeptide, relaxin-3, decreased self-administration of alcohol in a

67 Relaxin-3, the most recently identified member of relaxi

68 companying article, we present the case that relaxin-3, which has previously been shown to bind to th

69 However, unlike relaxin-3, which is also a potent agonist for GPCR135 an

70 In the medial septum, we observed relaxin-3-immunoreactive contacts with ChAT-, PV-, and g

71 behaves as an agonist for GPCR142 similar to relaxin-3.

72 s 35S-GTPgammaS incorporation in response to relaxin-3.

73 R142, which is also selectively activated by relaxin-3.

74 on, suggest that GPCR135 is the receptor for relaxin-3.

75 The mechanisms underlying the involvement of relaxin-3/GPCR135 in the regulation of stress, feeding,

76 further delineation of the functions of the relaxin-3/GPCR135 system.

77 A-chain from INSL5), the radiolabeled (125)I-relaxin-3/INSL5 chimera is a suitable ligand (high-affin

78 The relaxin-3/INSL5 chimeric peptide is a potential tool to

79 n of a selective GPCR135 agonist (a chimeric relaxin-3/INSL5 peptide designated R3/I5).

80 These data suggest that relaxin-3/RXFP3 signaling regulates alcohol intake and r

81 Dyspnoea improved with relaxin 30 microg/kg compared with placebo, as assessed

82 elaxin 10 microg/kg per day group, 42 in the relaxin 30 microg/kg per day group, 37 in the relaxin 10

83 Nonpregnant rats were treated with relaxin (4 mug/h, osmotic minipump), relaxin plus PPARga

84 sting inward remodeling that was reversed by relaxin (56+/-4 mum, P<0.05).

85 Relaxin, a hormone in the insulin superfamily, is synthe

86 Relaxin, a peptide hormone produced during pregnancy, is

87 The physiological effects of relaxin, a pleiotropic hormone with therapeutic potentia

88 Here, we demonstrate that H3 relaxin activates LGR7 but not LGR8.

89 Previously, we have shown that relaxin activates PPARgamma transcriptional activity in

90 These results suggest that relaxin activates the cAMP/PKA and p38 MAPK pathways to

91 Recent studies demonstrated that relaxin activates two orphan LGRs, LGR7 and LGR8, wherea

92 Relaxin activation of its receptor RXFP1 triggers multip

93 In the injured muscle, relaxin administration promoted the activation of Pax7-p

94 nal vascular changes induced by pregnancy or relaxin administration to nonpregnant rats.

95 ly change the renal vasodilatory response to relaxin administration.

96 Relaxin also increased PA distensibility in SHRs (34+/-2

97 Relaxin, an emerging pharmaceutical treatment for acute

98 osophila insulin-like peptide 8 (Dilp8) as a relaxin and insulin-like molecule secreted from growing

99 athway in the renal vasodilatory response to relaxin and pregnancy.

100 er there is local expression and function of relaxin and relaxin receptor in arteries of nonpregnant

101 in that the secondary interaction between H2 relaxin and RXFP1 is not driven by any single amino acid

102 vercome the many challenges of investigating relaxin and the LDLa module interactions with the ELs, w

103 interaction that involves the A-chain of H2 relaxin and transmembrane exoloops of the receptors.

104 suggest that urotensin II, apelin, ghrelin, relaxin and urocortins, together with the trace amine ty

105 Although binding sites for relaxin are widely distributed, the nature of its recept

106 The discontinuation of both doses of relaxin at week 24 led to statistically significant decl

107 n would be predicted to be most sensitive to relaxin-based therapies.

108 90 did not directly compete with orthosteric relaxin binding and did not affect binding kinetics, but

109 model explains the exquisite sensitivity of relaxin binding avidity to minute changes in the disposi

110 nown about the molecular mechanisms by which relaxin binding results in receptor activation.

111 e ability of H3 relaxin to compete for (33)P-relaxin binding to the chimeric receptor.

112 utated in RXFP1, and changes in function and relaxin binding were assessed alongside the RXFP1 agonis

113 rich G-protein-coupled receptor 7 supports a relaxin-binding group of amino acids that perfectly matc

114 H2 relaxin binds to the leucine-rich repeats of RXFP1 and R

115 operties to support further investigation of relaxin biology and animal efficacy studies of the thera

116 d no effect on increased distensibility with relaxin, but caused outward hypertrophic remodeling of P

117 a reporter gene assay to demonstrate that H2 relaxin can induce the expression of prostate-specific a

118 e have previously demonstrated that human H2-relaxin can mediate androgen-independent growth of LNCaP

119 is to elucidate the mechanism(s) by which H2-relaxin causes activation of the AR pathway.

120 Growing evidence indicates that circulating relaxin causes vasodilatation and increases in arterial

121 The ovarian peptide hormone, relaxin, circulates during pregnancy, contributing to pr

122 poprostenol, atrial natriuretic peptide, and relaxin (concentration range 10(-13) -10(-7)M).

123 f the secondary structure to the extent that relaxin cross-reacts with the LGR8, the RLF receptor.

124 These results suggest that relaxin crosses the BBB and activates MMP-2 in brain cor

125 The binding cassette of relaxin cuts at an angle of approximately 45 degrees acr

126 In addition, relaxin decreases endometrial levels of matrix metallopr

127 rthermore, nonreplicating viruses expressing relaxin did not increase metastases, suggesting that hig

128 Taken together, these results indicate that relaxin effects BMDEC function through the RXFP1 recepto

129 Thus, we hypothesized that relaxin enhances BMDEC NO production, circulating number

130 Results demonstrate that relaxin exerts dramatic uterine effects including pronou

131 throughout the tumor when compared with non-relaxin-expressing, Ad5-based viruses.

132 ccupied by STAT3 on day 6 of pregnancy, when relaxin expression is minimal; on day 15, when expressio

133 Downregulation of H2 relaxin expression results in significant inhibition of

134 ith STAT5 playing a role in the induction of relaxin expression.

135 Analyses of relaxin family genes on syntenic regions of model tetrap

136 acterization of contemporary and resurrected relaxin family hormones, we show that derivation of INSL

137 that the A-chains among some of the insulin/relaxin family members are pharmacologically exchangeabl

138 It interacts with two of the relaxin family peptide (RXFP) receptors.

139 al administration of peptide antagonists for relaxin family peptide 3 receptor (RXFP3), the cognate r

140 tment for acute heart failure, activates the relaxin family peptide receptor (RXFP1), which is a clas

141 tions through the G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), little is kno

142 nalosome, that couples the relaxin receptor, relaxin family peptide receptor 1 (RXFP1), to cAMP follo

143 and vasoprotective properties that binds to relaxin family peptide receptor-1 (RXFP1) and has been s

144 gnate G-protein coupled receptor for H2-RLX (relaxin family peptide receptor-1 (RXFP1)).

145 , a member of the highly conserved family of relaxin family peptide receptors (RXFPs), mediates the c

146 ies demonstrated that two of the seven human relaxin family peptides, relaxin H2 (RLN2) and INSL3, si

147 These neurons express the relaxin-family peptide, relaxin-3, and pharmacological m

148 t drivers of the affinity and activity of H2 relaxin for RXFP2 with additional minor contributions fr

149 t for 13 weeks and continuously treated with relaxin for the final 3 weeks of the diet exhibited decr

150 The Relaxin for the Treatment of Acute Heart Failure (RELAX-

151 In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study,

152 Expressing relaxin from Ad5/Ad35 fiber chimeric adenoviruses may pr

153 g that oncolytic adenoviruses expressing the relaxin gene and containing an Ad5/Ad35 chimeric fiber s

154 g/day and 25 microg/kg/day recombinant human relaxin, given for 24 weeks in patients with stable, dif

155 ital capacity decreased significantly in the relaxin groups.

156 of the seven human relaxin family peptides, relaxin H2 (RLN2) and INSL3, signal exclusively through

157 Relaxin had no vasodilator effect in pulmonary arteries.

158 The polypeptide hormone relaxin has been proven to be effective in promoting bot

159 is directly (bosentan, interferon gamma, and relaxin) have been disappointing but new strategies agai

160 The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX

161 on in various mammalian species, the role of relaxin in human reproduction is poorly understood, larg

162 er, the molecular and cellular mechanisms of relaxin in regulating both myogenic cell differentiation

163 documented importance of the protein hormone relaxin in reproduction in various mammalian species, th

164 ese results revealed the multiple effects of relaxin in systematically improving muscle healing as we

165 ty are consistent with a significant role of relaxin in the establishment and/or maintenance of early

166 These studies show the potential of relaxin in the treatment of diet-induced insulin resista

167 Relaxin increased the mRNA and protein levels of the coa

168 We show that the matrix-modifying hormone relaxin increased tumor-associated fibroblast (TAF) inte

169 re not detected in cerebral vasculature, but relaxin increased vascular endothelial growth factor (VE

170 The endogenous hormone relaxin increases vascular reactivity and angiogenesis.

171 -specific small interfering RNA inhibited H2-relaxin-induced AR activity.

172 GW9662 also prevented relaxin-induced changes in PPARgamma target gene express

173 to be involved in remodeling of PAs, but not relaxin-induced increased distensibility.

174 We demonstrate that acute relaxin infusion in lean C57BL/6J mice enhances skeletal

175 Exogenous relaxin inhibits MLC(20) phosphorylation and bleomycin-i

176 e 5 (INSL5) is a peptide that belongs to the relaxin/insulin family, and its receptor has not been id

177 in-3, the most recently identified member of relaxin/insulin family, is an agonist for leucine-rich r

178 h various A-chains from other members of the relaxin/insulin family.

179 in-like peptide 3 (INSL3) is a member of the relaxin/insulin superfamily and is expressed in testicul

180 efficient production platform for expressing relaxin/insulin superfamily peptides.

181 icacy studies of the therapeutic benefits of relaxin/insulin-like family peptide receptor 1 activatio

182 ent the first small-molecule series of human relaxin/insulin-like family peptide receptor 1 agonists.

183 linergic receptor, muscarinic 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1).

184 One lying upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (

185 function in adult males via interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).

186 d reduction in expression of INSL3 receptor, relaxin/insulin-like family peptide receptor 2 (RXFP2).

187 In BMDECs isolated from relaxin/insulin-like family peptide receptor 2 gene (Rxf

188 candidate genes, such as insulin-like 3 and relaxin/insulin-like family peptide receptor 2, in cases

189 Relaxin intervention improves endothelial-dependent vasc

190 Relaxin intervention reverses the accumulation of collag

191 tudies identify a novel antifibrotic role of relaxin involving the inhibition of the contractile phen

192 Relaxin is a 6 kDa protein hormone produced by the corpu

193 Relaxin is a hormone important for the growth and remode

194 Relaxin is a hormone that has been considered as a poten

195 Relaxin is a natural human peptide that affects multiple

196 To conclude, relaxin is a novel regulator of BMDECs number and functi

197 Relaxin is a peptide hormone that mediates antifibrotic

198 Relaxin is a powerful dilator of systemic resistance art

199 vessel disease (SVD), and determined whether relaxin is a treatment for SVD during hypertension.

200 dition, our previous study demonstrated that relaxin is beneficial to skeletal muscle healing by both

201 Thus, relaxin is bound by synchronized chelation of two argini

202 Relaxin is contraindicated due to inefficacy and severe

203 Human gene-2 (H2) relaxin is currently in Phase III clinical trials for th

204 Thus, we hypothesized that relaxin is involved in the selective outward remodeling

205 ain, the sharply defined binding cassette of relaxin is not present in RLF.

206 H2 relaxin is overexpressed in the LNCaP-R273H subline.

207 In addition, we demonstrate that H2 relaxin is responsible for facilitating p53(R273H)-media

208 The peptide hormone relaxin is showing potential as a treatment for acute he

209 If relaxin is used therapeutically for any conditions other

210 and bleomycin-induced lung fibrosis in both relaxin knockout and wild-type mice.

211 Compared with wild-type mice, relaxin knockout mice express higher lung levels of phos

212 ivation interaction of RXFP1 and RXFP2 by H2 relaxin, leading to a potent and RXFP1-selective analog,

213 , these findings reveal an arterial-derived, relaxin ligand-receptor system that acts locally to regu

214 The relaxin-like actions of CGEN25009 were abrogated by RXFP

215 The relaxin-like effects of CGEN25009 in vitro are dependent

216 lasts exhibited decreased sensitivity to the relaxin-like effects of CGEN25009.

217 The relaxin-like factor (RLF) also named insulin-like 3 (INS

218 uggest that the receptor-binding site of the relaxin-like factor (RLF) is located in the flexible C-t

219 The relaxin-like factor (RLF) is thought to be responsible f

220 Analogous to insulin, the relaxin-like factor (RLF) must undergo a structural tran

221 The relaxin-like factor (RLF), produced by the Leydig cells,

222 The relaxin-like factor (RLF, also named INSL3) is a critica

223 vered the signal initiation structure of the relaxin-like factor and shown its function to be indepen

224 s small protein permits one to study how the relaxin-like factor initiates the signal on the receptor

225 We tested CGEN25009, a relaxin-like peptide, in lung fibroblasts and in bleomyc

226 t targeting myofibroblast contractility with relaxin-like peptides may be of therapeutic benefit in t

227 tural and sexual selection at a single gene, relaxin-like receptor 2 (RXFP2).

228 In summary, the data show that relaxin may play a role in rearranging matrix components

229 Relaxin-mediated activation of RXFP1 requires multiple c

230 ponents of the Wnt pathway can facilitate H2-relaxin-mediated activation of the AR pathway.

231 t pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta an

232 Although it is known that relaxin mediates its actions through the G protein-coupl

233 lve parallel from the B-chain alpha-helix of relaxin, neutralize the charge repulsion of the juxta-po

234 ogenic therapeutic properties of recombinant relaxin peptide hormone have been investigated in severa

235 Relaxin peptides are important hormones for the regulati

236 ed with relaxin (4 mug/h, osmotic minipump), relaxin plus PPARgamma inhibitor GW9662 (10 mg/kg/d), or

237 Expression of relaxin precursor mRNA in rats is sharply induced after

238 These results suggest that relaxin produced during pregnancy may be partly responsi

239 Results showed that relaxin promoted myogenic differentiation, migration, an

240 strate that p53(R273H) binds directly to the relaxin promoter, further confirming a role for H2 relax

241 Relaxin provides a novel therapeutic approach targeting

242 eptor, formyl peptide receptor-2 (FPR2), the relaxin receptor (LGR7), G-proteins (Galpha(q/11/o/13)),

243 Because relaxin-3 also activates the relaxin receptor (LGR7), which is also expressed in the

244 local expression and function of relaxin and relaxin receptor in arteries of nonpregnant females and

245 ich has previously been shown to bind to the relaxin receptor LGR7, is most likely the endogenous lig

246 Activation of the relaxin receptor RXFP1 has been associated with improved

247 s indicate that the small molecules activate relaxin receptor through an allosteric site.

248 ly active GPCR signalosome, that couples the relaxin receptor, relaxin family peptide receptor 1 (RXF

249 sly been shown to bind and activate the LGR7 relaxin receptor.

250 Lgr3 is a member of the relaxin-receptor family and a receptor for Dilp8, necess

251 Relaxin receptors (RXFP1/2) were not detected in cerebra

252 as recently discovered as a novel ligand for relaxin receptors.

253 zation of the signaling pathway reveals that relaxin regulates MLC(20) dephosphorylation and lung myo

254 cells stably expressing RXFP1, we found that relaxin regulation of PPARgamma activity requires accumu

255 Administration of recombinant human relaxin (rhRLX) to conscious, chronically instrumented r

256 The relaxin (RLN) and insulin-like (INSL) gene family is a g

257 t-term administration of the peptide hormone relaxin (RLN).

258 w that inducible, intratumoral expression of relaxin (Rlx) either by transplanting tumor cells that c

259 prehensive evidence that the ovarian hormone relaxin (RLX) is responsible.

260 tools to study the physiological roles of H3 relaxin/RXFP3 systems in the brain and important leads f

261 We assessed the dose response of relaxin's effect on symptom relief, other clinical outco

262 RLF and relaxin share features of the secondary structure to the

263 were explored to assess whether intravenous relaxin should be pursued in larger studies of acute hea

264 n promoter, further confirming a role for H2 relaxin signaling in p53(R273H)-mediated AI CaP.

265 Relaxin significantly inhibits endometrial levels of est

266 Moreover, relaxin similarly promoted muscle healing in mice with a

267 The findings that relaxin stimulates new blood vessel formation and increa

268 During pregnancy, relaxin stimulates nitric oxide (NO)-dependent renal vas

269 udy was to elucidate the mechanisms by which relaxin stimulates the endothelial ETB receptor/NO vasod

270 Activated CREB was required for relaxin stimulation of PPARgamma activity, while there w

271 omized controlled trial of recombinant human relaxin suggested that a dosage of 25 microg/kg/day was

272 Relaxin-3 is the only member of the insulin/relaxin superfamily that can activate GPCR135.

273 ry mechanism for the extremely low levels of relaxin that circulate.

274 to develop analogues of human relaxin-3 (H3 relaxin) that can selectively bind and activate its rece

275 hypertension) in 7 patients who had received relaxin therapy but in none who had received placebo.

276 ccompanied by decreases in the ability of H3 relaxin to compete for (33)P-relaxin binding to the chim

277 nd primary human myoblasts were treated with relaxin to investigate its potential effect in vitro; re

278 Addition of H2-relaxin to LNCaP cells resulted in increased phosphoryla

279 th, whereas addition of recombinant human H2 relaxin to parental LNCaP promotes AI growth.

280 Relaxin treatment increased serum relaxin to the level of pregnancy (54 ng/ml) and increas

281 d inflammatory reaction was repressed in the relaxin-treated injured muscle.

282 MMP-2 activity in small renal arteries from relaxin-treated nonpregnant and midterm pregnant rats re

283 genic reactivity of these blood vessels from relaxin-treated nonpregnant and midterm pregnant rats wa

284 enic reactivity of small renal arteries from relaxin-treated nonpregnant and midterm pregnant rats.

285 enic reactivity of small renal arteries from relaxin-treated nonpregnant rats was absent in ETB recep

286 Length of stay was 10.2 days (SD 6.1) for relaxin-treated patients versus 12.0 days (7.3) for thos

287 ed renal vasodilation and hyperfiltration in relaxin-treated rats.

288 Relaxin treatment increased serum relaxin to the level o

289 21.0 in the D-Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial coh

290 ), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus p

291 nicillamine (D-Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine

292 o investigate its potential effect in vitro; relaxin was also injected intramuscularly into the injur

293 lure and normal-to-increased blood pressure, relaxin was associated with favourable relief of dyspnoe

294 In addition, relaxin was associated with serious renal adverse events

295 Relaxin was detected in cerebrospinal fluid (110+/-30 pg

296 Recombinant relaxin was not significantly better than placebo in imp

297 Human relaxin 3 (H3 relaxin) was recently discovered as a novel ligand for r

298 dies for rat and mouse Lgr7 receptor and rat relaxin, we also identified protein expression in arteri

299 s, such as urotensin-II, ghrelin, apelin and relaxin, which are most likely to provide novel targets

300 es, suggesting that high level expression of relaxin will not enhance metastatic spread of tumors.